Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Genmab
Genmab
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Drug Delivery
Partnership advances antibody therapies in immunology
Genmab and argenx have entered a multiyear collaboration, bringing together capabilities to jointly discover, develop and commercialise antibody therapies
Regulatory
ImaginAb announces supply agreement with Genmab
The non-exclusive worldwide agreement provides Genmab a license to use the company’s CD8 ImmunoPET imaging technology
Research & Development
Genmab and Synaffix enter into ADC license agreement
Genmab will be responsible for the research, development, manufacturing and commercialisation of any resulting ADC therapies
Manufacturing
Genmab chooses Ibex to take gene candidates to IND in 12 months
New contract extends the partnership between the Danish biotech company and Lonza
Research & Development
Personalised cancer treatment 2.0: new combination strategy developed
Tumours often comprise groups of cancer cells that show differential drug sensitivities, one of the reasons that initially effective treatments usually do not lead to long-term benefit in patients
Ingredients
Tisotumab Vedotin co-developed by Genmab and Seattle Genetics
Genmab and Seattle Genetics announced Seattle Genetics has exercised its option to co-develop tisotumab vedotin
Research & Development
Genmab appoints new CDO
Genmab appoints Judith Klimovsky as Executive Vice President and Chief Development Officer (CDO).
Subscribe now